Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:approvedBy |
gptkb:FDA
2000 |
| gptkbp:ATCCode |
J05AE06
|
| gptkbp:brand |
gptkb:Kaletra
|
| gptkbp:CASNumber |
192725-17-0
|
| gptkbp:chemicalFormula |
peptidomimetic
|
| gptkbp:combines |
gptkb:ritonavir
|
| gptkbp:contraindication |
severe liver impairment
|
| gptkbp:discoveredBy |
gptkb:Abbott_Laboratories
|
| gptkbp:drugClass |
protease inhibitor
|
| gptkbp:eliminationHalfLife |
5-6 hours
|
| gptkbp:hasMolecularFormula |
C37H48N4O5
|
| https://www.w3.org/2000/01/rdf-schema#label |
lopinavir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits HIV-1 protease
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
98-99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea hyperlipidemia |
| gptkbp:usedFor |
HIV/AIDS treatment
|
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:ritonavir
|
| gptkbp:bfsLayer |
6
|